Foghorn Therapeutics Announces Upcoming Investor Conference Participation [TheStreet.com]
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: TheStreet.com
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced management's participation in the following investor conferences. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases. Cowen's 3 rd Annual Oncology Innovation Summit: Insights for ASCO & EHA Thursday, June 2 nd, 10:30 a.m. ETPlease find a link to the fireside chat. Jefferies Healthcare Conference Wednesday, June 8 th, 1:30 p.m. ETPlease find a link to the fireside chat. Goldman Sachs 43rd Annual Global Healthcare Conference Monday, June 13 th, 3:20 p.m. PTPlease find a link to the fireside chat. A webcast of the panel can also be accessed under "Events & Presentatio
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerGlobeNewswire
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 8/4/23 - Beat
FHTX
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 3
- 4/16/24 - Form 8-K
- FHTX's page on the SEC website